ISRCTN13629652CompletedUnknown
An experimental medicine model for fast acting antidepressant drug treatment in treatment resistant depression
Conditions
Trial Snapshot
- Phase
- Unknown
- Status
- Completed
- Sponsor
- niversity of Oxford
- Enrollment
- 70
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •1. BMI between 18 and 30 kg/m²
- •2. Participant is willing and able to give informed consent for participation in the study
- •3. Sufficient knowledge of the English language to understand and complete study tasks
- •4. Willingness to refrain from driving, cycling, or operating heavy machinery, until the following morning or a restful sleep has occurred, whichever is later
- •5. Willingness to refrain from signing legal documents within 7 days after the infusion visit
- •6. Willingness to refrain from drinking alcohol for 3 days before the infusion visit and one day before any of the other visits throughout the study
Exclusion Criteria
- •1. Any current or past DSM-V significant psychiatric disorder including any psychotic, mood and anxiety and borderline personality disorders
- •2. History of, or current medical conditions which in the opinion of the investigator may interfere with the safety of the participant or the scientific integrity of the study, including epilepsy/seizures, brain injury, hepatic or renal disease, severe gastrointestinal problems, Central Nervous System (CNS) tumours, neurological conditions
- •3. First-degree relative with a diagnosis of schizophrenia-spectrum or other psychotic disorder, or bipolar disorder
- •4. History of unexplained hallucinations or impulse control problems (e.g. pathological gambling)
- •5. Current or past history of heart rhythm disorders
- •6. Clinically significant hypertension
- •7. Increased intraocular pressure/glaucoma
- •8. Current pregnancy (as determined by urine pregnancy test taken during Screening and Infusion Visits) or breastfeeding
- •9. Clinically significant abnormal values for clinical chemistry (e.g. liver function tests), urine drug screen, blood pressure measurement and ECG. A participant with a clinical abnormality or parameters outside the reference range for the population being studied may be included only if the Investigator considers that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures
- •10. Current or previous intake (last 3 months) of any medication that has a significant potential to affect mental functioning (e.g. benzodiazepines, antidepressants, neuroleptics etc)
- •11. Any intake of recreational drugs in the last 3 months (e.g. marijuana, ecstasy etc)
- •12. Lifetime recreational use of ketamine or phencyclidine
- •13. Regular alcohol consumption of more than 14 units a week or excessive alcohol consumption up to three days before any of the in-person study visits
- •14. Inability to abstain from alcohol for more than 1 week
- •15. Regular smoker (> 5 cigarettes per day)
- •16. Excessive caffeine user (> 6 caffeinated drinks per day)
- •17. History of recurrent rashes or history of allergic reactions to relevant substances (ketamine treatment, placebo treatment)
- •18. Previous participation in a study using the same or similar tasks
- •19. Current participation in another study or participation in a similar study within the last 6 months
- •20. Participant is unlikely to comply with the clinical study protocol or is unsuitable for any other reason, in the opinion of the Investigator
- •21. Claustrophobia
- •22. Any implants (including dental implants) or pacemaker
- •23. Tattoos above the chest
- •24. Any other MRI contraindications outlined in FMRIB 7 Tesla scanning safety form
Investigators
Similar Trials
Completed
Phase 4
A pilot study on the safety and efficacy of an antithrombotic therapy during carotid artery stenting (CAS).Those patients who have stenosis of more than 50% of the common carotid artery or internal carotid artery (diagnosed by ultrasonography or angiography), with neurological symptoms (transient cerebral ischemic stroke or cerebral stroke), or who have stenosis of more than 80% of the common carotid artery or internal carotid artery (diagnosed by ultrasonography or angiography) even if there are no neurological symptoms.JPRN-UMIN000002674Saitama medical university international medical center Department of Endovascular Neurosurgery50
Recruiting
Phase 4
In vivo evaluation of the effectiveness of two antiseptic solutions in reducing the viral load of SARS-CoV-2 in the saliva of patients with COVID-19Coronavirus infection of unspecified locationRBR-10hj7jynniversidade do Estado do Rio de Janeiro
Completed
Not Applicable
Investigation for safety and efficacy of a new antiseptic Olanexidine Gluconate in childrePatients who undergo surgery of catheter insertion or inguinal herniaJPRN-UMIN000027899ational Center for Child Health and Development55
Not yet recruiting
Unknown
Impact of medicines on red blood cellsCTRI/2024/04/065162Kasturba Medical College Manipal
Recruiting
Phase 1
A clinical study of the safety and efficacy of anti-epileptic drug Zonisamide for treatment of radiculopatyCervical spondylotic radiculopathyCervical spondylotic radiculopathy, cervical disc hernia, sensory impairmentD011843JPRN-jRCTs041210043Imagama Shiro24